Investing.com UK - Financial Markets Worldwide
Get 40% Off
Get 40% Off
💰 Buffett reveals a $6.7B stake in Chubb. Copy the full portfolio for FREE with InvestingPro’s Stock Ideas toolCopy Portfolio

TransMedics Stock Skyrockets, Analysts Call It 'One Of The Best Organic Growth Stories'

Published 01/05/2024, 18:13
Updated 01/05/2024, 19:40
© Reuters. TransMedics Stock Skyrockets, Analysts Call It 'One Of The Best Organic Growth Stories'
TMDX
-

Benzinga - by Vandana Singh, Benzinga Editor.

Tuesday, organ transplant-medical device firm TransMedics Group Inc (NASDAQ:TMDX) reported first-quarter EPS of 35 cents, a turnaround from an EPS loss of 8 cents a year ago, beating the consensus of a loss of 5 cents.

The company reported sales of $96.85 million, up 133% Y/Y, beating the consensus of $83.8 million, primarily due to the increase in utilization of the Organ Care System (OCS) across all three organs through the National OCS Program (NOP) as well as additional revenue generated by the addition of TransMedics logistics services.

The gross margin for the first quarter of 2024 was 62%, compared to 69% in the first quarter of 2023 and 59% in the fourth quarter of 2023.

Guidance: TransMedics raised its fiscal 2024 revenue guidance to $390 million-$400 million, up 61%-66% Y/Y, versus prior guidance of $360 million-$370 million and the consensus of $366.9 million.

William Blair views the first-quarter results and updated 2024 outlook as quite strong, and writes that TransMedics is “one of the best organic growth stories in their coverage universe.”

The analysts commend the integration of the National Organ Program (NOP) and the successful establishment of the aviation business, which is seen as boosting demand and enhancing the company’s competitive advantage.

The recent positive data presented at The International Society for Heart and Lung Transplantation is noted to generate ongoing interest in TransMedics’ OCS/NOP solutions among global transplant programs. Additionally, management’s announcement of three new clinical programs starting in late 2024 and early 2025 is seen as promising future catalysts by William Blair.

3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .

William Blair maintains the Outperform rating and sees the stock as a solid long-term growth holding.

Price Action: TMDX shares are up 27.3% at $119.90 at the last check Wednesday.

Now Read: DEA Moves To Reschedule Weed, Cannabis Stocks Go For Wild Ride, Pummel Short Sellers With $210M In Losses

Photo: Shutterstock

Latest Ratings for TMDX

Feb 2022Morgan StanleyMaintainsEqual-Weight
Jan 2022Morgan StanleyMaintainsEqual-Weight
May 2021Morgan StanleyMaintainsEqual-Weight

View the Latest Analyst Ratings

© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Read the original article on Benzinga

Latest comments

Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.